GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Shares Buyback Ratio %

CPRX (Catalyst Pharmaceuticals) Shares Buyback Ratio % : -11.88 (As of Dec. 11, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Catalyst Pharmaceuticals's current shares buyback ratio was -11.88%.

Catalyst Pharmaceuticals Shares Buyback Ratio % Historical Data

The historical data trend for Catalyst Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Shares Buyback Ratio % Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.64 -0.37 0.76 -2.20 -1.77

Catalyst Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.48 -10.18 -0.42 -0.63

Catalyst Pharmaceuticals Shares Buyback Ratio % Calculation

Catalyst Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(105.263 - 107.122) / 105.263
=-1.77%

Catalyst Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Sep. 2024 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(118.521 - 119.267) / 118.521
=-0.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Shares Buyback Ratio %
Comparable Companies
IOVA SLNO JANX APGE GERN ACAD ZLAB PTGX LBPH SRRK VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CN2:Germany CN2:Germany
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Website
https://www.catalystpharma.com
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Richard J Daly director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286